Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Paula Rodriguez-OteroSikander AilawadhiBertrand ArnulfKrina PatelMichele CavoAjay K NookaSalomon ManierNatalie CallanderLuciano José Megale CostaRavi VijNizar J BahlisPhilippe MoreauScott R SolomonMichel DelforgeJesus BerdejaAnna Truppel-HartmannZhihong YangLinda Favre-KontulaFan WuJulia PiaseckiMark CookSergio GiraltPublished in: The New England journal of medicine (2023)
Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class-exposed relapsed and refractory multiple myeloma who had received two to four regimens previously. The toxicity of ide-cel was consistent with previous reports. (Funded by 2seventy bio and Celgene, a Bristol-Myers Squibb company; KarMMa-3 ClinicalTrials.gov number, NCT03651128.).